In our current study, we chose a broad spectrum MMP substrate, but future work can employ alternate, more narrowly susceptible substrates to look more directly at how knockdown of a given target influences particular cancer hallmarks, such as angiogenesis (MMP1,2,9; KLK 2,6,7), inflammation (MMP8, ADAM17, and Legumain), or immune evasion (MMP8,12; DPP4). The gene discussed is ADAM17; the disease is cancer.